STOCK TITAN

Cardiff Oncology Inc - CRDF STOCK NEWS

Welcome to our dedicated news page for Cardiff Oncology (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cardiff Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cardiff Oncology's position in the market.

Rhea-AI Summary
Cardiff Oncology, Inc. announces the presentation of five abstracts at the AACR Annual Meeting, showcasing the potential of onvansertib in various cancer indications. Key highlights include improved outcomes in KRAS-mutant mCRC patients not exposed to bevacizumab, robust antitumor activity of onvansertib in RAS wild-type colorectal cancer, and promising synergies with paclitaxel in small cell lung cancer and carboplatin/gemcitabine in platinum-resistant ovarian carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.77%
Tags
conferences
-
Rhea-AI Summary
Cardiff Oncology, Inc. (CRDF) announces positive clinical data for RAS-mutated mCRC trials, with cash reserves of $75 million till Q3 2025. The company's lead program, onvansertib, shows promising results in treating mCRC, with upcoming data readouts expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.87%
Tags
earnings
-
Rhea-AI Summary
Cardiff Oncology, Inc. (CRDF) provides a clinical update on the ONSEMBLE trial for RAS-mutated mCRC patients, showcasing the efficacy of onvansertib in combination with FOLFIRI/bev. The company shifted its focus to first-line mCRC in agreement with the FDA, discontinuing the ONSEMBLE trial. The data from the trial supports the potential of onvansertib in improving outcomes for patients in the first-line setting. Cardiff Oncology plans to release the topline results of the CRDF-004 trial in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.87%
Tags
clinical trial
Rhea-AI Summary
Cardiff Oncology, Inc. initiates Phase 2 trial CRDF-004 for RAS-mutated mCRC patients with the drug onvansertib in combination with standard-of-care (SoC) treatment, aiming to provide a new therapy option after almost two decades. Pfizer Ignite is overseeing the trial execution, with encouraging Phase 1b/2 results supporting the potential efficacy of onvansertib. The trial will assess safety, efficacy, and dose confirmation for onvansertib in the first-line setting, with anticipated Phase 3 trial CRDF-005 and FDA accelerated approval considerations based on interim ORR results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.87%
Tags
none
-
Rhea-AI Summary
Cardiff Oncology, Inc. (CRDF) will participate in the Cowen 44th Annual Health Care Conference with a fireside chat led by CEO Mark Erlander on March 4, 2024. The company aims to leverage PLK1 inhibition for novel cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
conferences
-
Rhea-AI Summary
Cardiff Oncology, Inc. (CRDF) will release financial results for Q4 and full year 2023 on February 29, 2024. The company focuses on developing cancer therapies using PLK1 inhibition. A conference call and webcast will be held to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences earnings
Rhea-AI Summary
Cardiff Oncology, Inc. announced the publication of findings from the Phase 1b portion of the Phase 1b/2 study for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The results highlight the safety and promising efficacy of onvansertib in combination with standard-of-care chemotherapy+bevacizumab. The study revealed an improved objective response rate and median progression-free survival compared to historical controls, demonstrating efficacy across multiple KRAS mutations. The company has also received agreement from the US FDA to initiate a first-line trial in RAS-mutated mCRC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.82%
Tags
clinical trial
-
Rhea-AI Summary
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced their participation in the 35th Annual Piper Sandler Healthcare Conference in New York. CEO Mark Erlander will be presenting at the fireside chat on 11/29/2023, discussing the company's innovative PLK1 inhibition therapies for cancer. Interested parties can register for the live webcast on the Cardiff Oncology website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
-
Rhea-AI Summary
Cardiff Oncology announced positive clinical and preclinical data for their lead program in RAS-mutated metastatic colorectal cancer (mCRC). They also expanded their relationship with Pfizer for a new Phase 2 trial. Onvansertib monotherapy showed activity in refractory patients with small cell lung cancer. The company has approximately $81.4 million in cash and expects to fund operations into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
earnings
Rhea-AI Summary
Cardiff Oncology plans to release financial results for the third quarter on November 2 and will hold a conference call and webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences earnings
Cardiff Oncology Inc

Nasdaq:CRDF

CRDF Rankings

CRDF Stock Data

256.89M
41.29M
7.56%
15.17%
2.59%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About CRDF

trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh